FDA Withdraws Approval of Neomycin Sulfate Compounder Application

Summary

The FDA is withdrawing approval of an Abbreviated New Drug Application (ANDA) for a nonsterile neomycin sulfate powder used in prescription compounding due to concerns over its safety. The product has been linked to significant toxicity, including hearing loss, kidney damage, and muscle weakness.